News Search Results
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,' will be featured in the Investigational Immunotherapy session (Presentation Number 1553P). It can be viewed on October 19, 2025,
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,' will be featured in the Investigational Immunotherapy session (Presentation Number 1553P). It can be viewed on October 19, 2025,
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin annonce la présentation de données de phase I sur le LNP3693 (agoniste de STING) au congrès ESMO 2025
intitulée « A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma » (Étude d'augmentation de dose de phase I de LNP3693 (agoniste de STING) chez les patients atteints de tumeurs solides au stade avancé ou métastatiques
More news about: Lupin Limited
Oct 09, 2025, 09:30 ET My Fairy Godfathers Foundation Celebrates 'Oscar Night' Raising Nearly $200K at Annual Charity Ball in Tampa, FL
human spirit was the heartfelt speech from wig and beauty experience recipient, Arianna Murrow of New York. She was diagnosed with stage 2 Hodgkin's Lymphoma as a high school senior and met with an avalanche of emotions. "Cancer wouldn't take my hope. I submitted college applications from my hospital bed
More news about: My Fairy Godfathers
Oct 08, 2025, 12:27 ET Rotary Air Preheaters Market Size to Reach USD 1.8 Billion by 2033, Growing at 5.2% CAGR from 2026-2033 - Market Research Intellect
Global Checkpoint Inhibitors For Treating Cancer Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors (Programmed Death-Ligand 1), CTLA-4 Inhibitors
More news about: Market Research Intellect
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. LYMPHIR, approved by the FDA in August 2024 for relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, targets an initial U.S. market that management estimates exceeds $400 million and continues to grow.
More news about: Equity Insider
Oct 08, 2025, 08:00 ET BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 08, 2025, 07:00 ET Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 11:03 ET John Hyland, CFP® Honored with the Invest in Others Charitable Foundation's Second Executive Tribute for Outstanding Financial Services Leadership and Commitment to Giving Back
exceptional financial services leadership and ongoing commitment to raising funds and awareness for Blood Cancer United, formerly the Leukemia & Lymphoma Society.
More news about: Invest in Others Charitable Foundation
Oct 07, 2025, 10:00 ET Maria Fareri Children's Hospital Earns First-Ever National Ranking from US News & Report as Among the Best Children's Hospitals
also was recently awarded an Empire Clinical Research Investigator (ECRIP) grant of $459,333 to advance safer, more precise treatments for Hodgkin's lymphoma, particularly in children and adolescents. "For our patients and families, being named one of the Top 50 children's hospitals
More news about: WMCHealth
Oct 07, 2025, 08:47 ET Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
About Cutaneous T-cell Lymphoma (CTCL) Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that
More news about: Citius Oncology, Inc.
Oct 07, 2025, 08:30 ET Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Oct 07, 2025, 07:30 ET Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
enroller in the Phase 3 FLASH study. About Cutaneous T-Cell Lymphoma (CTCL) CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike
More news about: SOLIGENIX, INC.
Oct 07, 2025, 06:10 ET Ryght AI Assembles Renowned Medical Leaders to Guide Next Phase of Clinical Trial AI Innovation
BMBCh, FRCP Professor and Head, Department of Dermatology, St George Hospital Alan Skarbnik, MD Director, Lymphoma & CLL Program, Director Immune Effector Cell Therapeutics Program, Novant Health Vivek Subbiah, MDChief, Early-Phase
More news about: Ryght
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
GAZYVA/GAZYVARO (obinutuzumab) is an engineered monoclonal antibody, administered intravenously, that targets the CD20 protein expressed on lymphoma and leukemia cells. Unlike traditional CD20 antibodies, it binds specifically to Type 2 CD20, resulting in stronger antibody-dependent cytotoxicity
More news about: DelveInsight Business Research, LLP
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
year), a major risk factor for peptic ulcer disease (90% of cases)15 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma16. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients
More news about: RedHill Biopharma Ltd.
Oct 03, 2025, 16:00 ET Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia
More news about: Curis, Inc.
Oct 02, 2025, 19:30 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot as a Pinnacle Lifetime Member
Oncology and the American College of Radiation Oncology. His commitment to giving back is reflected in his volunteer efforts with the Leukemia and Lymphoma Society's annual Light the Night event and his involvement with Connecting Champions, where he works with children recovering from cancer.
More news about: The Inner Circle